The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in Hepg 2.2.15 by He, Hai Bin et al.
KOWSAR
Hepat Mon. 2011;11(5):364-367
Journal home page: www.HepatMon.com
A
r
t
i
c
l
e
 
O
n
l
i
n
e
 
S
u
b
m
i
s
s
i
o
n
 
a
t
:
W
W
W
.
H
E
P
A
T
M
O
N
.
C
O
M
Number 34, Volume 11, Issue 5, My 2011
Inactive Carrier and 
HBV Reactivation
HBV DNA and ALT predict 
2-year response to LAM 
HBsAg and HBS DNA 
levels in chronic HBV
LATEST
IMPACT FACTOR
0.716
Official Monthly Journal of the Baqiyatallah Research Center for Gastroenterology and Liver Diseases
ISSN: Print 1735-143x,   Online 1735-3408
The effect of desacetyluvaricin on the expression of TLR4 and P53 protein in 
Hepg 2.2.15
Hai Bin He 1∆, Xian Lin Wu 2∆, Bin Yu 2, Kang Li Liu 2, Guang Xiong Zhou 3, Guo Qiang Qian 2, 
Da Hong Ju 4, Xiao Yin Chen 2*
1 Department of Gastroenterology, the People’s Hospital of Heshan, Guangdong, China
2 Department of Traditional Chinese Medicine, Medicine College of Jinan University, Guangzhou, China
3 Pharmaceutical College of Jinan University, Guangzhou, China
4 Institute of Basic Theories of Traditional Chinese Medicine, China Academy of Traditional Chinese Medicine, Beijing, China
ABSTRACT
Background: Previous studies suggest that annonaceous may cause permeability glyco-
protein (P-gp) function to abate, leading to cell apoptosis. It has also been reported 
that annonaceous acetogenins affect hepatocellular carcinoma (HCC) cells in the G1 
phase, leading to apoptosis. Desacetyluvaricin (Des), a new type of annonaceous ac-
etogenin monomer, has a significant effect on HCC, with few side effects.
Objectives: To investigate the effect of Des on the expression of Toll-like receptor 4 
(TLR4) and P53 protein in HCC.
Materials and Methods: HCC HepG2.2.15 cell was cultured by routine method. HepG2.2.15 
cells were divided into three groups: control group, treated with Des and DDP (cispla-
tin) which were examined by immunofluorescence flow cytometry for expression of 
TLR4 and P53.
Results: TLR4 was expressed by more cells in the Des group than in the cisplatin or 
serum-only groups (71.94%, 42.64%, and 37.16%, respectively; Des vs.cisplatin: p < 0.05; 
Des vs. serum only: p < 0.05), with no difference between the cisplatin and serum-only 
groups (p > 0.05). P53 was expressed by more cells in the Des and cisplatin groups 
than in the serum-only group (32.6%, 31.5% and 3.3%, respectively; Des vs. serum only, 
p < 0.05; cisplatin vs. serum only, p < 0.05), with no difference between the Des and 
cisplatin groups (p > 0.05).
Conclusions: Des increases TLR4 and P53 expression in HCC cells. Improved immune 
recognition by the former effect and induction of apoptosis by the latter could be the 
mechanisms of Des’s clinical effects on HCC.
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Background
In 1982, Tempesta isolated uvaricin, a lactone with strong 
anti-cancer activity, from the roots of Uvaria accuminata 
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of the family Annonaceae (1). Annonaceous acetogenin 
compounds are considered a promising natural source 
of anti-tumor compounds, and an increasing amount of 
research is being done on this compound. Studies sug-
gest that annonaceous acetogenins’ anti-tumor mecha-
nism may be through inhibition of mitochondrial NADH 
oxido-reductase, preventing the transmission of respira-
tory chain electrons and producing a rapid decrease in 
ATP levels. This, in turn, causes a decrease in permeabil-
ity glycoprotein (P-gp) function, leading to cell apoptosis 
(2). It is reported that annonaceous acetogenins affect 
tumor cells in the G1 phase, inducing BAX expression, 
increasing caspase-3 activity, and finally inducing apop-
tosis (3, 4). However, it is not clear whether annonaceous 
acetogenin’s anti-tumor effect is achieved by increasing 
immune function.
Des (Des), a type of annonaceous acetogenin mono-
mer extract from the traditional Chinese medicine, has 
demonstrated a significant effect on liver cancer (5). Our 
research group previously showed that Des can block 
mitosis in hepatocellular carcinoma (HCC) cells in vitro, 
inhibiting cell proliferation (6). We found that Des in-
duced Fas expression better than cisplatin (Cis-diammin-
odichloroplatinum Ц dichloridle, DDP). We also showed 
that Des’s effect on inhibiting tumor cells was similar to 
chemotherapy drug cisplatin. However, when hepatitis 
B virus (HBV) was added to the cell cultures, Des’s effect 
to induce Fas expression was greater than chemotherapy 
drug cisplatin. We speculated that Des may enhance im-
mune function.
Objectives
To further elucidate the anti-HCC role of Des and its 
mechanism in enhancing immune function on the 
HepG2.2.15, we used monomer and DDP to intervene, and 
then detect the expression of TLR4 and P53, to observe 
the effects on HepG2.2.15 treated by Des and hope to re-
veal the mechanism.
Materials and Methods
Reagents and instruments
Dulbecco's modified Eagle medium (DMEM) was pro-
duced by GIBCO Company, USA; fetal calf serum (FCS) was 
produced by SiJiQing Biomedical Materials Engineering 
Research Institute, Hangzhou, China; Phycoerythrin 
(PE)-TLR4 antibody (PE-anti-TLR4) and PE-mouse IgG2a 
was produced by Ebioscience Company, San Diego, USA; 
PE-anti-P53 was produced by AbDSerotec Company; BD 
FACS Calibur flow cytometer was produced by COULPER 
Company and provided by the First Affiliated Hospital of 
Sun Yat-sen University.
Treatments
DDP was provided by Qilu Pharmaceutical CO, Ltd, Ji-
nan, China, batch number: 703012CF; Des was provided 
by Guang Xiong Zhou who produced it in his laboratory, 
Pharmaceutical College of Jinan University. (Figure 1)
Cancer cell line
The HCC cell line HepG2.2.15 was provided by Ming-xia 
Zhang, Southern Medical University in Guangzhou, Chi-
na.
Cell culture and treatment exposure
HepG2.2.15 cells were incubated in 10% inactivated FCS 
DMEM (pus G418) at 37°C and 5% CO2 in normal culture 
passage. Logarithmic phase cells were selected with 1 mL 
of 0.25% trypsin, washed, replated onto a 12-well plate 
at a concentration of 3×104 cells/mL, and incubated at 
37°C and 5% CO2 for 48 hours. At the 48th hour, the cells 
entered the exponential growth phase. Cells were then 
washed and 0.5 mL of either FCS (negative control), FCS 
containing 100 μg/mL Des, or FCS containing 10 μg/mL 
DDP (positive control) was added to relevant wells (7). The 
culture plate was then incubated for another 48 hours at 
37°C and 5% CO2. Five such plates were prepared.
Detection of TLR4 and P53 expression
After incubation, cells were washed and tagging with 
fluorescent antibodies for either TLR4 or P53, as follows 
(8, 9). For each of the three treatment groups, cells were 
incubated for 48 hours, 1 mL of 0.25% trypsin was added 
to digest, then centrifuged to collect cells, and then com-
bined into a single suspension of 1×106 cells. For P53 mea-
surements, cells were incubated instead with 1% Triton 
X-100; then we added 10 μL PE-anti-P53 and 100 μL cells 
suspension. For TLR4 measurements, we added 10 μL PE-
anti-TLR4 and 100 μL cells suspension. Cells were washed 
with phosphate buffered saline (PBS). We followed the 
above-mentioned methods to make the same type of 
control except that we used 10 μL of PE-mouse IgG2a in-
stead of PE-anti-TLR4 or PE-anti-P53, as control group. The 
suspensions were then mixed and incubated for 20 min-
Figure 1. Des chemical structure (molecular formula C37H66O6)
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Expression of P53 after Des
The Mean ± SD P53-positive rates in the Des, DDP and 
serum-only groups were 32.6% ± 1.7%, 31.5% ± 1.3%, and 3.3% 
± 0.6%, respectively (Figure 3 and Table 1). There was no dif-
ference between the Des and DDP groups (p = 0.000). 
The expression of P53 in both groups was significantly 
higher than that in the serum-only group (p < 0.001 for 
both). 
Discussion
TLRs play an important role in the host immune re-
sponse to pathogenic microorganisms. They can identify 
molecules of pathogenic microorganisms in the innate 
immune system, and initiate the innate immune re-
sponse. TLRs also can induce cytokine release, increase 
the expression of co-stimulatory molecules, and initiate 
the acquired immune response (11). Recent research has 
shown that TLR4-deficient mice have a higher incidence 
of lung cancer than normal mice, suggesting that TLR4 
has a preventive role in genesis of tumors (12). We found 
that Des increased expression of TLR4 in HCC cells. This 
mechanism, via TLR4’s stimulation of the immune re-
sponse, may explain Des’ inhibiting effect on HCC.
P53, which is encoded by the tumor suppressor gene 
P53, has two independent HBV X protein (HBx) binding 
sites, located in the P53-specific DNA binding and oli-
gomerization areas (13). HBx-P53 complexes have been 
found in the cytoplasm of liver cells; it has been shown 
that their binding is reversible. By binding to P53, HBx 
prevents P53 trans-activation, thus inhibiting P53-guided 
apoptosis (14). This may play an important role in HBV’s 
hepatocarcinogenesis. In liver nuclei, low levels of P53 
support cell division at the G1 phase and block apoptosis, 
while high levels of P53 cells can be lead to apoptosis (15). 
When HBx binds P53, the complex can block the nuclear 
P53, leading to lower concentrations of P53, which inhib-
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Figure 3. P53 expression in HepG2.2.15 hepatocellular carcinoma cells, 
measured by immunofluorescence flow cytometry. Standard: Standard cali-
bration. Control: Serum-only treated; DES: Desacetyluvaricin-treated; DDP: 
Cisplatin-treated
Figure 2. TLR4 expression in HepG2.2.15, measured by immunofluorescence 
flow cytometry. X-axis is the cell number, Y-axis is the fluorescence. CD284: 
TLR4expression; Standard: Standard calibration. Control: serum-only treated; 
DES: Desacetyluvaricin-treated; DDP: Cisplatin-treated
utes at room temperature in the dark; then suspensions 
of all the studied groups were centrifuged at 1000 rps 
for 5 minutes; PBS was added to 106/mL dubbed liquid. 
The cells were examined by direct immunofluorescence 
flow cytometry (10) and the number of positive cells was 
counted. Five such plates were prepared.
Statistical analysis
The results were presented as Mean ± SD. SPSS® for Win-
dows® (Ver 13.0; SPSS, Chicago, IL, USA) was used for data 
analysis. The proportion of positive cells was calculated 
for each of the five experiments and the results were then 
averaged. The treatment and control groups were evalu-
ated using analysis of variance. A p < 0.05 was considered 
statistically significant.
Results
Expression of TLR4 after Des
Among Des-treated cells, the Mean ± SD TLR4-positive 
rate was 71.94% ± 1.04%, significantly higher than that ob-
served in the DDP group (42.64% ± 0.83%, p < 0.001) or the 
serum-only group (37.16% ± 1.33%, p < 0.001) (Figure 2 and 
Table 1). There was no significant difference between the 
DDP and serum-only groups (p = 0.128).
Group Positive rate of 
CD284 (%)
Positive rate of 
P53 (%)
Control 37.16 ± 1.33 3.3 ± 0.6
Desacetyluvaricin 71.94 ± 1.04 a, b 32.6 ± 1.7 a, b
DDP 42.64 ± 0.83 a 31.5 ± 1.3%
Table 1.  Mean ± SD expression of TLR4 (CD284) and P53 (No. = 5)
a Significantly (p < 0.05) different from control group
b Significantly (p < 0.05) different from DDP groupHepat Mon. 2011;11(5):364-367
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its apoptosis. We found that Des increased expression of 
P53 in HCC cells. Thus, this may be an additional mecha-
nism for Des’ anti-cancer effect, which is different from 
the mechanism of annonaceous acetogenin-induced 
apoptosis (2).
In summary, our results show that Des’ effect against 
HCC cells may be through upregulating expression of 
TLR4 and P53, which ultimately activates the innate im-
mune response, allowing the immune system to clear 
cancer cells.
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